Endophytic bacteria from brassica crops as bio-factories of antimicrobial compounds for sustainable agriculture

Overview

This research presents endophytic bacteria isolated from Brassica crops that function as natural bio-factories of antimicrobial compounds. Three selected bacterial isolates have demonstrated strong biocontrol potential through multiple mechanisms, including the production of antimicrobial peptides, secondary metabolites, lipopeptides, and volatile compounds. These bioactives effectively inhibit the growth of important bacterial and fungal phytopathogens, offering a sustainable alternative to chemical pesticides for crop disease management.

The isolates were screened in dual culture assays against key plant pathogens, with cell-free supernatants achieving inhibition rates ranging from 40 to 100%. Peptide fractions showed the highest efficacy, reaching 100% inhibition against both bacteria and fungi, while volatile compounds released by the isolates inhibited fungal growth by 50-80%. This multi-mechanism approach makes these endophytes versatile tools for integrated pest and disease management strategies.

Technical specifications

Key features and capabilities:

• Three characterized endophytic bacterial isolates with confirmed plant-growth promoting traits
• Production of antimicrobial peptides with up to 100% inhibition of bacterial and fungal pathogens
• Secondary metabolites and lipopeptides fractions with demonstrated antimicrobial activity
• Volatile organic compounds that inhibit fungal growth by 50-80%
• Semi-purification strategies established for different compound classes
• Potential for transgenic strain development to overexpress biosynthetic genes and increase compound yields

Research approach:

• Compound identification via mass spectrometry to characterize the chemical nature of antimicrobial peptides, secondary metabolites, and volatile compounds
• Whole genome sequencing of isolates to identify genes involved in antimicrobial compound biosynthesis
• Development of transgenic strains designed to overexpress biosynthetic genes for enhanced production
• Optimization of culture conditions and purification strategies to maximize compound yields
• Field validation of compounds and whole bacteria for disease management applications

Technology readiness level

The technology is currently at TRL 3-4 (analogous to experimental proof-of-concept and laboratory validation). The collection of endophytic bacteria has been established, three isolates have been selected and identified, and initial validation through dual culture assays has confirmed antimicrobial efficacy. Semi-purification protocols have been developed for different compound fractions.

Future validation steps include mass spectrometry-based compound identification, genomic sequencing to identify biosynthetic genes, creation of overexpressing transgenic strains, and field trials to confirm efficacy under real agricultural conditions. The research team is actively seeking partnerships that can provide financial and technical support for compound identification and strain sequencing to advance toward commercial application.